Purpose of this Study
We are doing this study to find out how safe and effective an experimental drug called MVR-C5252 (the study drug) is for people with advanced brain cancer.
Who Can Participate?
Eligibility
Adults ages 18+ who are diagnosed with recurrent high-grade glioma.
For more information about this study, please call 919-668-3726.
For more information about this study, please call 919-668-3726.
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
If you join the study, you will:<ul>
<li>Have a physical and neurological exam and other tests</li>
<li>Have magnetic resonance imaging (MRI) of the brain</li>
<li>Have blood draws</li>
<li>Have brain tumor biopsy and testing of tumor sample</li>
<li>Have a catheter (small flexible tube) placed in and around the tumor with the other end of the catheter extending slightly outside of the head</li>
<li>Get the study drug infused through an external pump and the implanted catheter</li></ul>
<li>Have a physical and neurological exam and other tests</li>
<li>Have magnetic resonance imaging (MRI) of the brain</li>
<li>Have blood draws</li>
<li>Have brain tumor biopsy and testing of tumor sample</li>
<li>Have a catheter (small flexible tube) placed in and around the tumor with the other end of the catheter extending slightly outside of the head</li>
<li>Get the study drug infused through an external pump and the implanted catheter</li></ul>
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
The PuMP Trial: A Multistage Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252 in Patients with Recurrent High-Grade Glioma
Principal Investigator
Mustafa
Khasraw
Protocol Number
PRO00112883
NCT ID
NCT06126744
Phase
I
Enrollment Status
Open to Enrollment